Aerovate Therapeutics, Inc. (AVTE)

Aerovate Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	33.75	23.49	22.4	54.2	4.57
Short-Term Investments	44.87	98.95	106.82	113.18	-
Cash & Short-Term Investments	78.62	122.44	129.22	167.38	4.57
Cash Growth	-35.79%	-5.25%	-22.80%	3560.07%	30.14%
Prepaid Expenses	0.65	1.54	1.98	6.72	0.07
Other Current Assets	0.85	0.25	0.3	0.24	0.04
Total Current Assets	80.12	124.23	131.5	174.33	4.68
Property, Plant & Equipment	0.22	0.9	1.25	0.73	0.04
Other Long-Term Assets	-	2.28	2.56	0.3	-
Total Assets	80.33	127.42	135.3	175.36	4.72

Liabilities

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Accounts Payable	0.22	2.4	2.58	1.21	0.61
Accrued Expenses	2.87	13.73	4.44	1.01	1.14
Current Portion of Leases	0.42	0.42	0.39	0.19	-
Other Current Liabilities	0.32	1.09	0.38	0.14	0.02
Total Current Liabilities	3.83	17.64	7.78	2.55	1.77
Long-Term Leases	-	0.26	0.71	0.38	-
Other Long-Term Liabilities	0.07	0.07	0.07	0.01	-
Total Liabilities	3.9	17.96	8.56	2.95	1.77

Shareholders' Equity

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Common Stock	0	0	0	0	-
Additional Paid-In Capital	309.38	272.64	215.11	208.87	0.06
Retained Earnings	-233.05	-163.42	-87.9	-36.39	-13.41
Comprehensive Income & Other	0.11	0.24	-0.47	-0.06	-
Total Common Equity	76.43	109.46	126.74	172.42	-13.34
Shareholders' Equity	76.43	109.46	126.74	172.42	2.94
Total Liabilities & Equity	80.33	127.42	135.3	175.36	4.72

Additional Metrics

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Total Debt	0.42	0.68	1.09	0.57	-
Net Cash (Debt)	78.21	121.76	128.13	166.8	4.57
Net Cash Growth	-35.77%	-4.97%	-23.18%	3547.52%	350.99%
Net Cash Per Share	2.74	4.62	5.24	13.57	18.88
Filing Date Shares Outstanding	28.99	27.86	24.81	24.41	0.24
Total Common Shares Outstanding	28.99	27.76	24.72	24.41	0.24
Working Capital	76.29	106.6	123.71	171.78	2.9
Book Value Per Share	2.64	3.94	5.13	7.06	-54.90
Tangible Book Value	76.43	109.46	126.74	172.42	-13.34
Tangible Book Value Per Share	2.64	3.94	5.13	7.06	-54.90

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2024

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jan 1, 2000

Data Sources Report a data error